Please login to the form below

Not currently logged in


This page shows the latest Zantac news and features for those working in and with pharma, biotech and healthcare.

Perrigo expands consumer health with €3.6bn Omega purchase

Perrigo expands consumer health with €3.6bn Omega purchase

Belgium-based Omega has also expanded in recent years purchasing several over-the-counter (OTC) medicines from GlaxoSmithKline (GSK) in 2012, including Lactacyd, Abtei, Solpadeine, Zantac, Nytol and Beconase.

Latest news

  • GSK plans to sell off older products GSK plans to sell off older products

    Imitrex (sumatriptan) for migraine, the antidepressant Paxil/Seroxat (paroxetine) and gastrointestinal therapy Zantac (ranitidine) have all been named in dispatches as former blockbuster brands that are now in GSK's 'established

  • Boehringer creates ‘Captain Zantac’ Boehringer creates ‘Captain Zantac

    This is an exciting new chapter in the evolution of the Zantac brand," said Ross Ullman, executive director of marketing, Boehringer Ingelheim Consumer Healthcare. . ... Zantac has been a leader in heartburn relief for more than two decades.

  • GSK sells Lucozade and Ribena for £1.35bn GSK sells Lucozade and Ribena for £1.35bn

    This was followed in March 2012 by the sale to Belgian company Omega of brands such as Lactacyd, Abtei, Solpadeine, Zantac, Nytol and Beconase for £391m and then a month later

  • Report suggests GSK on brink of consumer health sale

    US private equity firm Thomas H Lee Partners seen as lead candidate to take over various brands including Alli, Solpadeine and Zantac. ... weight loss product Alli (orlistat), analgesics such as Solpadeine and OTC version of gastrointestinal drug Zantac

  • Healthy Investment

    We now know that the difficult days of the mid-1980s gave way to a golden age for pharmaceuticals, marked by hugely successful products such as Zantac, Prozac, Losec/Prilosec, Zocor,

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Interview: Laure Thibaud, Sanofi Interview: Laure Thibaud, Sanofi

    It was also the dawn of the industry's blockbuster era, which for Glaxo meant the years of its star-performing indigestion and heartburn treatment Zantac.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...